These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 24464803

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE.
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [Abstract] [Full Text] [Related]

  • 45. Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor.
    Oda K, Cao YJ, Sawamoto T, Nakada N, Fisniku O, Nagasaka Y, Sohda KY.
    Xenobiotica; 2015 Aug; 45(10):887-902. PubMed ID: 25986538
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. In Vitro Kinetic Characterization of Axitinib Metabolism.
    Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D, Smith BJ.
    Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.
    Zhou X, Pusalkar S, Chowdhury SK, Searle S, Li Y, Ullmann CD, Venkatakrishnan K.
    Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
    [Abstract] [Full Text] [Related]

  • 54. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
    Tiseo PJ, Perdomo CA, Friedhoff LT.
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
    [Abstract] [Full Text] [Related]

  • 55. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
    Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
    [Abstract] [Full Text] [Related]

  • 56. Tofacitinib: A New Oral Therapy for Psoriasis.
    Azevedo A, Torres T.
    Clin Drug Investig; 2018 Feb; 38(2):101-112. PubMed ID: 29094282
    [Abstract] [Full Text] [Related]

  • 57. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S, Tan EY, Hartmann G, Biddle Z, Bergman AJ, Dru J, Ho JZ, Jones AN, Staskiewicz SJ, Braun MP, Karanam B, Dean DC, Gendrano IN, Graves MW, Wagner JA, Krishna R.
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [Abstract] [Full Text] [Related]

  • 58. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G.
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [Abstract] [Full Text] [Related]

  • 59. Effects of naringenin on the pharmacokinetics of tofacitinib in rats.
    Wang B, Shen J, Zhou Q, Meng D, He Y, Chen F, Wang S, Ji W.
    Pharm Biol; 2020 Dec; 58(1):225-230. PubMed ID: 32202190
    [Abstract] [Full Text] [Related]

  • 60. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S.
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.